비강 스프레이 시장 규모, 점유율, 성장 및 세계 산업 분석 : 종류별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of nasal spray Market

The global nasal spray market was valued at USD 32.43 billion in 2025 and is projected to grow to USD 35.26 billion in 2026, reaching USD 70.17 billion by 2034, with a CAGR of 8.90% during 2026-2034. North America dominated the market in 2025 with a 44.01% share, driven by the high prevalence of nasal allergies, allergic rhinitis, and sinus infections, alongside the advantages of precise, painless drug delivery and patient convenience.

Nasal sprays are devices designed for nasal drug delivery to treat conditions such as allergic rhinitis, sinus infections, asthma, and central nervous system disorders. Products available in the market include corticosteroids, saltwater solutions, topical decongestants, antihistamines, and others, with corticosteroids being the most widely used due to their efficacy in treating nasal congestion, sneezing, watery eyes, and runny nose.

Impact of COVID-19

The COVID-19 pandemic caused a temporary decline in nasal spray sales due to weakened cold and flu seasons and social distancing measures. For example, GSK plc experienced an 8.3% revenue drop for its Avamys/Veramyst nasal spray in 2020, and AstraZeneca reported a 32.1% decline for Pulmicort nasal spray. However, by 2021, sales began to recover, and in 2022, new product launches contributed to significant revenue growth, setting the stage for the projected market expansion.

Market Trends

Pharmaceutical companies and private organizations are increasingly investing in R&D activities for novel nasal spray formulations. For instance, in 2022, SK Bioscience partnered with IAVI for developing an antiviral nasal spray, receiving a USD 2.2 million grant from the Bill & Melinda Gates Foundation. Rising healthcare expenditure and improved healthcare infrastructure also contribute to this trend.

Growth Drivers

Increasing Prevalence of Respiratory Disorders

Chronic respiratory diseases, including asthma, COPD, occupational lung diseases, and pulmonary hypertension, are rising globally due to factors such as smoking, pollution, and childhood infections. According to the CDC, asthma prevalence increased from 7.4% in 2001 to 7.7% in 2021. Nasal sprays help alleviate symptoms, improve airflow, and enhance patient comfort, driving demand in the market.

Strong Pipeline of Product Approvals

Companies such as GSK plc, Viatris Inc., Emergent Devices, Cipla, and Pfizer are continuously launching new nasal spray products. Notable approvals include naloxone hydrochloride nasal spray for opioid overdose (2023) and ZAVZPRET for acute migraine treatment (2023). Such regulatory approvals boost market growth and accessibility.

Restraining Factors

Side effects from nasal sprays, including nasal dryness, inflammation, congestion, bitter taste, and CNS or cardiovascular risks, may limit adoption. Additionally, the use of compounded drugs not approved by the FDA poses safety risks and can restrain market expansion.

Segmentation Analysis

By Product Type:

• Corticosteroids dominated with 42.71% market share in 2026, treating allergic rhinitis, sinusitis, and nasal polyps.
• Saltwater solutions are projected to grow fastest due to over-the-counter availability without prescriptions.

By Application:

• Nasal allergies led the market with 45.57% share in 2026, driven by increased patient demand and new product approvals.
• Asthma is expected to grow fastest, reflecting rising respiratory disorders.

By Age Group:

• Adults accounted for 72.57% share in 2026, due to higher prevalence of respiratory diseases.
• Pediatrics is projected to grow rapidly, supported by products like Afrin nasal spray for children (2022).

By Type:

• Prescription segment led in 2026 with 61.81% share, due to frequent launches of generic and novel drugs.
• Over-the-counter nasal sprays are growing steadily, aided by online sales and private-label products.

By Distribution Channel:

• Drug stores & retail pharmacies held the highest share due to wide availability.
• Hospital pharmacies accounted for the second-largest share.
• Online pharmacies are growing rapidly due to increasing internet penetration and discounts.

Regional Insights

• North America dominated with USD 15.50 billion in 2026; U.S. market projected at USD 5.49 billion.
• Europe held second place; UK at USD 1.32 billion, Germany at USD 1.79 billion in 2026.
• Asia Pacific expected fastest growth; Japan USD 1.54 billion, China USD 2.3 billion, India USD 1.58 billion in 2026.
• Latin America & Middle East & Africa hold growth potential due to rising nasal allergies and expanding healthcare access.

Competitive Landscape

Key players include GSK plc, Johnson & Johnson Services, Viatris Inc., Emergent Devices, Cipla, Bayer AG, Aurena Laboratories, Aytu Health, Procter & Gamble, and AstraZeneca. Companies focus on product approvals, launches, partnerships, and geographic expansion. Recent developments include OTC naloxone nasal sprays (2023) and antiviral sprays targeting COVID-19.

Conclusion

The global nasal spray market, valued at USD 32.43 billion in 2025, increased to USD 35.26 billion in 2026 and is projected to reach USD 70.17 billion by 2034. Growth is driven by increasing prevalence of respiratory disorders, strong product pipelines, rising adoption of corticosteroids, strategic R&D initiatives, and expanding healthcare infrastructure across key regions.

Segmentation By Product Type

• Corticosteroids
• Salt Water Solutions
• Topical decongestants
• Antihistamine
• Others

By Application

• Nasal Allergies
• Cold
• Asthma
• Others

By Age Group

• Pediatric
• Adults

By Type

• Prescription Based
• Over-the-Counter

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Product Type, Application, Age Group, Type, Distribution Channel, and Country)
  • U.S. (By Product Type)
  • Canada (By Product Type)
• Europe (By Product Type, Application, Age Group, Type, Distribution Channel, and Country/ Sub-region)
  • The U.K. (By Product Type)
  • Germany (By Product Type)
  • France (By Product Type)
  • Italy (By Product Type)
  • Spain (By Product Type)
  • Scandinavia (By Product Type)
  • Rest of Europe (By Product Type)
• Asia Pacific (By Product Type, Application, Age Group, Type, Distribution Channel, and Country/ Sub-region)
  • China (By Product Type)
  • Japan (By Product Type)
  • India (By Product Type)
  • Australia (By Product Type)
  • Southeast Asia (By Product Type)
  • Rest of Asia Pacific (By Product Type)
• Latin America (By Product Type, Application, Age Group, Type, Distribution Channel, and Country/ Sub-region)
  • Brazil (By Product Type)
  • Mexico (By Product Type)
  • Rest of Latin America (By Product Type)
• Middle East & Africa (By Product Type, Application, Age Group, Type, Distribution Channel, and Country/ Sub-region)
  • GCC (By Product Type)
  • South Africa (By Product Type)
  • Rest of Middle East & Africa (By Product Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence/ Incidence of Nasal Infection, By Key Countries, 2025
• 4.2. Technological Advancements in Nasal Spray
• 4.3. Key Industry Developments, By Key Players
• 4.4. Impact of COVID-19 on the Market

5. Global Nasal Spray Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Corticosteroids
  • 5.1.2. Salt Water Solutions
  • 5.1.3. Topical decongestants
  • 5.1.4. Antihistamine
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Nasal Allergies
  • 5.2.2. Cold
  • 5.2.3. Asthma
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Prescription Based
  • 5.4.2. Over-the-Counter
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Drug Stores & Retail Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Nasal Spray Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Corticosteroids
  • 6.1.2. Salt Water Solutions
  • 6.1.3. Topical decongestants
  • 6.1.4. Antihistamine
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Nasal Allergies
  • 6.2.2. Cold
  • 6.2.3. Asthma
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Prescription Based
  • 6.4.2. Over-the-Counter
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Drug Stores & Retail Pharmacies
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Product Type
  • 6.6.2. Canada
    • 6.6.2.1. By Product Type

7. Europe Nasal Spray Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Corticosteroids
  • 7.1.2. Salt Water Solutions
  • 7.1.3. Topical decongestants
  • 7.1.4. Antihistamine
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Nasal Allergies
  • 7.2.2. Cold
  • 7.2.3. Asthma
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Prescription Based
  • 7.4.2. Over-the-Counter
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Drug Stores & Retail Pharmacies
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. U.K.
    • 7.6.1.1. By Product Type
  • 7.6.2. Germany
    • 7.6.2.1. By Product Type
  • 7.6.3. France
    • 7.6.3.1. By Product Type
  • 7.6.4. Italy
    • 7.6.4.1. By Product Type
  • 7.6.5. Spain
    • 7.6.5.1. By Product Type
  • 7.6.6. Scandinavia
    • 7.6.6.1. By Product Type
  • 7.6.7. Rest of Europe
    • 7.6.7.1. By Product Type

8. Asia Pacific Nasal Spray Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Corticosteroids
  • 8.1.2. Salt Water Solutions
  • 8.1.3. Topical decongestants
  • 8.1.4. Antihistamine
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Nasal Allergies
  • 8.2.2. Cold
  • 8.2.3. Asthma
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Prescription Based
  • 8.4.2. Over-the-Counter
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Drug Stores & Retail Pharmacies
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
    • 8.6.1.1. By Product Type
  • 8.6.2. Japan
    • 8.6.2.1. By Product Type
  • 8.6.3. India
    • 8.6.3.1. By Product Type
  • 8.6.4. Australia
    • 8.6.4.1. By Product Type
  • 8.6.5. Southeast Asia
    • 8.6.5.1. By Product Type
  • 8.6.6. Rest of Asia Pacific
    • 8.6.6.1. By Product Type

9. Latin America Nasal Spray Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Corticosteroids
  • 9.1.2. Salt Water Solutions
  • 9.1.3. Topical decongestants
  • 9.1.4. Antihistamine
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Nasal Allergies
  • 9.2.2. Cold
  • 9.2.3. Asthma
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Prescription Based
  • 9.4.2. Over-the-Counter
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Drug Stores & Retail Pharmacies
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
    • 9.6.1.1. By Product Type
  • 9.6.2. Mexico
    • 9.6.2.1. By Product Type
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Product Type

10. Middle East & Africa Nasal Spray Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Corticosteroids
  • 10.1.2. Salt Water Solutions
  • 10.1.3. Topical decongestants
  • 10.1.4. Antihistamine
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Nasal Allergies
  • 10.2.2. Cold
  • 10.2.3. Asthma
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Prescription Based
  • 10.4.2. Over-the-Counter
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Drug Stores & Retail Pharmacies
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
    • 10.6.1.1. By Product Type
  • 10.6.2. South Africa
    • 10.6.2.1. By Product Type
  • 10.6.3. Rest of Middle East & Africa
    • 10.6.3.1. By Product Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Viatris Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Emergent Devices, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Cipla, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Bayer AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Aurena Laboratories
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Aytu Health (Innovus Pharmaceutical)
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. The Procter & Gamble Company
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. AstraZeneca
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)
  • 11.2.10. Johnson & Johnson Services, Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Product
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. financials (Based on Availability)